Eight genes (CHGA, CPE, ENO2, INSM1, PTPRN2, SERPINA10, and SLC18A1/2) that have been previously identified as markers of neuroendocrine tumors [28]–[31] were confirmed in this study to be altered. This evidence concerns the gene SLC18A1 and neuroendocrine neoplasm.